CatalYm has announced the closure of an oversubscribed EUR50 million Series C financing round that was co-led by new investors, Brandon Capital and Jeito Capital, with participation from existing investors Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, BioGeneration Ventures and Coparion. …
Australian venture capital fund joins partners in backing new immunotherapy
November 24, 2022 Latest NewsAustralian Biotech
Latest Video
New Stories
-
The 'Dispatched' Podcast - Series 5, Ep.25
July 24, 2026 - - Podcast -
Finalists named for the 2026 Patient's Choice awards
July 24, 2026 - - Latest News -
Australian company moving headquarters to US and restructuring workforce
July 24, 2026 - - Latest News -
The 'end of days' language is just a farcical attempt to shut down discussion
July 24, 2026 - - Latest News -
How national HPV vaccination programs are changing the story of cervical cancer
July 23, 2026 - - Latest News -
Faster processes could push Pharmac's options for investment backlog to 400 within two years
July 23, 2026 - - Latest News -
Bellberry and ASCEPT release checklist for 'new approach methodologies' trials
July 23, 2026 - - Latest News